Gill David N
- SEC CIK
- 0001106519
No open-market purchases or sales filed in the past year.
Current role at each company
- EOLS Evolus, Inc.Directoras of Feb 19, 2026
- YMAB Y-mAbs Therapeutics, Inc.Directoras of Sep 18, 2025
- SBBP Strongbridge Biopharma plcDirectoras of Oct 6, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Gill David N as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
EOLS Evolus, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2024 (view filing) | May 13-14 | 2 days | Gill David NDirector | SSale | −10.4K | $12.64 | −$131.0K | −23.4%34.0K after | 2 lots |
| May 17, 2022 (view filing) | May 13-16 | 4 days | Gill David NDirector | SSale | −10.3K | $13.35 | −$137.7K | −25.9%29.6K after | 2 lots |